Showing results (1021-1030 of 1,104) with videos related to
Sort By:
Pageof 111
BJU International|June 5, 2024
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlatesAndrew W Hahn, Ganiraju C Manyam, Brian F Chapin, et al.Nature Communications|August 5, 2024
A neurodevelopmental disorder mutation locks G proteins in the transitory pre-activated stateKevin M Knight, Brian E Krumm, Nicholas J Kapolka, et al.Cancer|April 3, 2015
Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man studyRenata Pasqualini, Randall E Millikan, Dawn R Christianson, et al.Iscience|July 11, 2022
Erratum: The origin of bladder cancer from mucosal field effectsJolanta Bondaruk, Roman Jaksik, Ziqiao Wang, et al.Cancer|March 29, 2016
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancerShi-Ming Tu, Mehmet Asim Bilen, Kenneth R Hess, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerSusan Halabi, Qian Yang, Akash Roy, et al.Iscience|June 24, 2022
The origin of bladder cancer from mucosal field effectsJolanta Bondaruk, Roman Jaksik, Ziqiao Wang, et al.Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.Cancers|July 9, 2022
Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) ComponentsRama Soundararajan, Paul Viscuse, Patrick Pilie, et al.Pageof 111